CCR4 and neoplasm: In a melanoma study, CCR4 was required for the homing Tregs to nascent tumor sites from LNs, and BRAFV600E signaling controlled the expression of CCR4 chemokines, raising the possibility that inhibiting this signaling with BRAF inhibitors may have reduced Treg recruitment to the tumor [168].